Home
ABBV
ABBV News

Latest AbbVie Inc. (ABBV) News on October 8, 2025

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

Zacks

a day ago

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

3 Dividend Stocks to Double Up On Right Now

Motley Fool

a day ago

3 Dividend Stocks to Double Up On Right Now

Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know

Zacks

2 days ago

Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know

AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?

Zacks

2 days ago

AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?

MT Newswires

2 days ago

AbbVie Says Botox Met Primary Endpoint in Phase 2 Upper Limb Essential Tremor Trial

Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk

Zacks

2 days ago

Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

PR Newswire

2 days ago

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results

Zacks

2 days ago

How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

PR Newswire

2 days ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

5 Large Cap Drug Stocks: Values or Traps?

Zacks

5 days ago

5 Large Cap Drug Stocks: Values or Traps?

MT Newswires

5 days ago

AbbVie Says $2.7 Billion in Costs Seen Cutting Q3 EPS by $1.50

How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment

Investor's Business Daily

5 days ago

How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment

Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?

Zacks

5 days ago

Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?

MT Newswires

5 days ago

TD Cowen Adjusts Price Target on AbbVie to $280 From $250, Maintains Buy Rating

Does AbbVie's (ABBV) Manufacturing Expansion Signal a Shift in Its Long-Term Growth Focus?

Simply Wall St.

5 days ago

Does AbbVie's (ABBV) Manufacturing Expansion Signal a Shift in Its Long-Term Growth Focus?

Bernstein Remains a Hold on AbbVie Inc. (ABBV)

Insider Monkey

5 days ago

Bernstein Remains a Hold on AbbVie Inc. (ABBV)

Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery

Insider Monkey

5 days ago

Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery

2 Healthcare Stocks to Research Further and 1 Facing Challenges

StockStory

5 days ago

2 Healthcare Stocks to Research Further and 1 Facing Challenges

AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why

Zacks

6 days ago

AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why

MT Newswires

6 days ago

Calico, AbbVie's Investigational Kidney Disease Drug Gets FDA Fast Track Designation

Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease

PR Newswire

6 days ago

Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

PR Newswire

6 days ago

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations

Newsfile

6 days ago

Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations

AbbVie (ABBV) Advances Parkinson’s Treatment With Tavapadon NDA

Insider Monkey

6 days ago

AbbVie (ABBV) Advances Parkinson’s Treatment With Tavapadon NDA

Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance

Insider Monkey

6 days ago

Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance

Why AbbVie Stock Cruised to an Almost 6% Gain Today

Motley Fool

7 days ago

Why AbbVie Stock Cruised to an Almost 6% Gain Today

Why AbbVie (ABBV) Stock Is Trading Up Today

StockStory

7 days ago

Why AbbVie (ABBV) Stock Is Trading Up Today

AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability

Insider Monkey

7 days ago

AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability

2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi

GlobeNewswire

7 days ago

2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi

MT Newswires

7 days ago

AbbVie Unit Signs Supply Deal With Vizient for Natrelle Breast Implants

MT Newswires

7 days ago

Climb Bio Names Dr. Susan Altschuller CFO

Natrelle® Awarded Supplier Agreement from Vizient

PR Newswire

7 days ago

Natrelle® Awarded Supplier Agreement from Vizient

MT Newswires

7 days ago

Bristol-Myers Squibb, Takeda Join Apheris' OpenFold3 Drug Discovery AI Model

Presbyopia Market Research Report 2025-2035 | FDA-Approved Eye Drops, Advanced IOLs and Personalized Medicine Drive Global Growth Amid Aging Population

GlobeNewswire

7 days ago

Presbyopia Market Research Report 2025-2035 | FDA-Approved Eye Drops, Advanced IOLs and Personalized Medicine Drive Global Growth Amid Aging Population

Bristol Myers, Takeda to pool data for AI-based drug discovery

Reuters

7 days ago

Bristol Myers, Takeda to pool data for AI-based drug discovery

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

Motley Fool

7 days ago

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

MT Newswires

8 days ago

AbbVie Submits Biologics License Application to FDA for Rare Blood Cancer Treatment

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

PR Newswire

8 days ago

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

AbbVie Inc.(ABBV) Unit Expands Skin Solution Availability amid $5.2B Opportunity

Insider Monkey

8 days ago

AbbVie Inc.(ABBV) Unit Expands Skin Solution Availability amid $5.2B Opportunity

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

GlobeNewswire

9 days ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease

Zacks

9 days ago

AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease

MT Newswires

9 days ago

Sector Update: Health Care Stocks Edge Lower Monday Afternoon

MT Newswires

9 days ago

AbbVie Begins Construction of Manufacturing Facility in North Chicago

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

PR Newswire

9 days ago

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

MT Newswires

9 days ago

AbbVie Prices Ovarian Cancer Drug Elahere in UK That is Equal to US List Prices

AbbVie to launch ovarian cancer drug in UK at US price

Reuters

9 days ago

AbbVie to launch ovarian cancer drug in UK at US price

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

PR Newswire

9 days ago

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

Assessing AbbVie (ABBV) Valuation After FDA Filing for New Parkinson’s Drug Tavapadon

Simply Wall St.

10 days ago

Assessing AbbVie (ABBV) Valuation After FDA Filing for New Parkinson’s Drug Tavapadon

Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.

Barrons.com

12 days ago

Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.

Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?

Zacks

12 days ago

Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?

MT Newswires

12 days ago

AbbVie Submits Marketing Application for Parkinson's Drug Candidate to FDA

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

PR Newswire

12 days ago

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

Eli Lilly, Pfizer Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.

Barrons.com

12 days ago

Eli Lilly, Pfizer Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.

Dr. Robert Lenz Joins Unlearn as Strategic Advisor

Business Wire

13 days ago

Dr. Robert Lenz Joins Unlearn as Strategic Advisor

QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published

CNW Group

13 days ago

QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published

3 Top Dividend Stocks to Buy and Hold Forever

Motley Fool

13 days ago

3 Top Dividend Stocks to Buy and Hold Forever

Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai

PR Newswire

13 days ago

Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai

Where Will AbbVie Be in 5 Years?

Motley Fool

13 days ago

Where Will AbbVie Be in 5 Years?

AbbVie (ABBV) Declines More Than Market: Some Information for Investors

Zacks

14 days ago

AbbVie (ABBV) Declines More Than Market: Some Information for Investors

MT Newswires

14 days ago

Leerink Partners Adjusts Price Target on AbbVie to $243 From $210, Maintains Outperform Rating

Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis

Insider Monkey

15 days ago

Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis

These Dividend Stocks Have Big Yields and Are Beating the Odds

Barrons.com

15 days ago

These Dividend Stocks Have Big Yields and Are Beating the Odds

MT Newswires

15 days ago

Amneal Pharmaceuticals Says FDA Approved Abbreviated NDA for Bimatoprost Ophthalmic Generic

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

GlobeNewswire

15 days ago

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

MT Newswires

15 days ago

AbbVie to Launch Skinvive in 35 Additional Markets

Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality

PR Newswire

15 days ago

Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality

1 Top Dividend Stock to Buy and Hold Forever

Motley Fool

16 days ago

1 Top Dividend Stock to Buy and Hold Forever

Piper Sandler Reiterates Its ‘Overweight’ Rating on AbbVie Inc. (ABBV) with a $231 PT

Insider Monkey

16 days ago

Piper Sandler Reiterates Its ‘Overweight’ Rating on AbbVie Inc. (ABBV) with a $231 PT

What Is One of the Best Pharmaceutical Stocks to Buy Right Now?

Motley Fool

16 days ago

What Is One of the Best Pharmaceutical Stocks to Buy Right Now?

Forever Dividend Stocks: 3 Income Stocks I Never Plan to Sell

Motley Fool

16 days ago

Forever Dividend Stocks: 3 Income Stocks I Never Plan to Sell

AbbVie Inc. (ABBV) Extends Rinvoq Patent to 2037, Delaying Generics

Insider Monkey

17 days ago

AbbVie Inc. (ABBV) Extends Rinvoq Patent to 2037, Delaying Generics

Dividend Paying Stocks With Stability: AbbVie’s (ABBV) Consistent Record

Insider Monkey

17 days ago

Dividend Paying Stocks With Stability: AbbVie’s (ABBV) Consistent Record

The Year’s Biggest Deal Could Yield a Record Payout for Bank of America

The Wall Street Journal

18 days ago

The Year’s Biggest Deal Could Yield a Record Payout for Bank of America

H.C. Wainwright Affirms ‘Buy’ Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects

Insider Monkey

18 days ago

H.C. Wainwright Affirms ‘Buy’ Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects

Boost Your Portfolio With These Top-Ranked ETFs

Zacks

19 days ago

Boost Your Portfolio With These Top-Ranked ETFs

Morningstar Research

19 days ago

Analyst Report: AbbVie Inc.

The Zacks Analyst Blog Highlights AbbVie, ServiceNow, Boeing, Tucows and and Ampco-Pittsburgh

Zacks

19 days ago

The Zacks Analyst Blog Highlights AbbVie, ServiceNow, Boeing, Tucows and and Ampco-Pittsburgh

3 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off

Motley Fool

19 days ago

3 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off

Top Analyst Reports for AbbVie, ServiceNow & Boeing

Zacks

20 days ago

Top Analyst Reports for AbbVie, ServiceNow & Boeing

J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

Zacks

20 days ago

J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

BMO Lifts AbbVie Inc. (ABBV) Price Target to $240 After Rinvoq Litigation Win

Insider Monkey

20 days ago

BMO Lifts AbbVie Inc. (ABBV) Price Target to $240 After Rinvoq Litigation Win

MT Newswires

20 days ago

Alnylam Joins Alliance for Genomic Discovery

AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note

Zacks

21 days ago

AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note

Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker

Investor's Business Daily

21 days ago

Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker

MT Newswires

21 days ago

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT Newswires

21 days ago

Sector Update: Health Care

MT Newswires

21 days ago

AbbVie Shares Rise After Berenberg Upgrade

Should You Buy This Blue-Chip Dividend Stock at Record Highs?

Barchart

21 days ago

Should You Buy This Blue-Chip Dividend Stock at Record Highs?

Netflix upgraded, Five Below initiated: Wall Street's top analyst calls

The Fly

21 days ago

Netflix upgraded, Five Below initiated: Wall Street's top analyst calls

Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker

Investor's Business Daily

21 days ago

Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker

MT Newswires

21 days ago

Berenberg Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $270 From $170

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227

Insider Monkey

22 days ago

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227

Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?

Zacks

22 days ago

Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?

AbbVie (ABBV)’s Dividend Track Record: How It Became a Leader in Consistent Dividends

Insider Monkey

22 days ago

AbbVie (ABBV)’s Dividend Track Record: How It Became a Leader in Consistent Dividends

Assessing AbbVie After Neuro Pipeline Expansion and Double Digit 2025 Share Gains

Simply Wall St.

22 days ago

Assessing AbbVie After Neuro Pipeline Expansion and Double Digit 2025 Share Gains

MT Newswires

22 days ago

JPMorgan Adjusts Price Target on AbbVie to $235 From $200, Maintains Overweight Rating

MT Newswires

23 days ago

AbbVie Says Vraylar Antipsychotic Medication Now Listed on Alberta's Health Drug Formulary

MT Newswires

23 days ago

Deutsche Bank Adjusts Price Target on AbbVie to $204 From $173

AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta

CNW Group

23 days ago

AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta

Saisei Ventures Appoints James Feliciano as Venture Partner

Business Wire

23 days ago

Saisei Ventures Appoints James Feliciano as Venture Partner

Share on Social Networks: